Sector BioCryst Pharmaceuticals, Inc.

Aandelen

BCRX

US09058V1035

Biotechnologie & Medisch Onderzoek

Geschatte realtime 16:40:26 27-10-2026 Variatie 5 dagen Verschil t.o.v. 1 jan (%)
7,985 USD +1,33% Intraday-grafiek van BioCryst Pharmaceuticals, Inc. +0,31% +2,12%
Belangrijkste concurrenten
Verschil (%) Varia. 5d. Evolutie 1 maand Evolutie 3 maanden Var. 1 jan Varia. 1j. Varia. 3j. Varia. 5j. Varia. 10j. Kap.($)
+1,33%+0,31%-5,96%-16,86%+2,12%+8,96%+50,00%-46,65%+84,80% 2,01 mld.
-3,10%-3,43%-12,88%+13,18%+56,09%+36,29%+67,69%+1,93% - 65,28 mld.
+0,28%+0,23%-7,41%-0,99%+9,10%+10,05%+77,89%+225,29%+5.446,10% 54,57 mld.
-0,19%+1,38%+8,46%+13,26%+17,81%+9,51%+101,40%-16,08%+258,37% 53,59 mld.
+0,62%+2,78%+1,60%+29,12%+22,13%+26,62%+53,00%+8,26%+281,83% 45,03 mld.
-1,79%-5,74%-1,24%+11,21%+19,30%+14,90%+112,64%-1,32%+1.004,66% 42,17 mld.
+0,90%-5,81%-8,23%-1,56%+132,43%+219,24%+894,79%+571,00% - 39,42 mld.
-0,74%-4,84%+6,31%+6,19%+9,41%+14,53%+44,45%+3,10%+154,40% 32,71 mld.
-2,70%-7,34%-15,74%+14,22%+42,05%+23,17%+0,36%-62,78% - 24,01 mld.
+1,18%+15,26%+30,28%+57,18%+47,95%+60,37%+49,43%+3,27%+162,61% 26,5 mld.
-0,12%-5,22%-12,79%-5,14%-9,23%-18,52%-5,25%-69,00% - 21,82 mld.
+1,67%-0,88%-19,41%-9,46%-45,52%-42,19%+297,09%+259,19%+589,14% 20,38 mld.
+0,26%+8,67%+9,81%+14,76%+20,43%+13,39%+170,25%+221,17%+2.253,43% 18,93 mld.
-0,05%+13,20%+21,22%+59,21%+79,02%+82,87%+106,91%-16,97%+366,92% 17,06 mld.
-0,44%+8,30%+8,69%+27,85%+37,12%+38,94%+84,87%-16,45%+107,77% 16,69 mld.
+0,27%+1,41%+11,87%+17,00%+48,98%+63,29%+223,27%+206,57%+497,99% 16,13 mld.
+0,35%+5,02%+6,98%-2,89% - - - - - 16,1 mld.
+2,59%+1,28%+3,03%+4,85%+180,86%+162,43%+375,61%+1.411,75%+779,81% 14,75 mld.
+0,49%+6,03%+5,19%+9,42%+1,35%+1,46%-21,51%-34,45%+129,48% 14,18 mld.
-5,62%+0,27%-2,96%-11,83%+15,55%+3,56%+512,43% - - 14,63 mld.
Gemiddelde -0,26%+3,76%+1,34%+11,44%+36,15%+38,36%+168,17%+147,10%+865,52% 27,8 mld.
Gewogen gemiddelde per kap. -0,49%+2,90%-0,15%+12,54%+36,43%+39,06%+163,23%+121,92%+1.226,83%
  1. Beurs
  2. Aandelen
  3. Koers BCRX
  4. Sector BioCryst Pharmaceuticals, Inc.